3 Results for "

primary central nervous system lymphoma

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "primary central nervous system lymphoma" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-12868
CAS No.: 1225037-39-7
Purity:  98.62%
Synonyms: PQR309
Target:  

PI3K mTOR Apoptosis

Research Areas:  

Cancer

Bimiralisib (PQR309) is an orally active, blood-brain barrier-penetrant PI3K/mTOR inhibitor with in vitro antiproliferative activity and in vivo antitumor activity. Bimiralisib induces G1 cell cycle arrest, apoptosis and cell death in cancer cells, while inhibiting cancer cell proliferation, migration, invasion, colony formation and spheroid generation. Bimiralisib upregulates the expression of E2F4. The combination of Bimiralisib with venetoclax enhances therapeutic efficacy in acute myeloid leukemia models. Bimiralisib can be used in cancer-related research .
loading...
    loading...
Cat. No.: HY-187684
CAS No.: 3054389-11-3
Target:  

CRM1 Apoptosis

Research Areas:  

Neurological Disease Cancer

FR-027 is an orally active, blood-brain barrier permeable XPO1 inhibitor with an EC50 value of 54-69 nM in human cells. FR-027 covalently modifies Cys528 of XPO1 via nucleophilic aromatic substitution, maintaining the nuclear export signal binding groove of XPO1 in a closed conformation to block the nuclear export process, and inhibits XPO1 function without inducing its protein degradation. FR-027 promotes cancer cell apoptosis and inhibits the growth of hematological and solid tumor cells. FR-027 can be used in research related to acute lymphoblastic leukemia, ovarian cancer, glioblastoma, and primary central nervous system lymphoma .
loading...
    loading...
Cat. No.: HY-12868A
CAS No.: 1820902-72-4
Synonyms: PQR309 hydrochloride
Target:  

PI3K mTOR Apoptosis

Research Areas:  

Cancer

Bimiralisib hydrochloride (PQR309 hydrochloride) is an orally active, blood-brain barrier-penetrant PI3K/mTOR inhibitor with in vitro antiproliferative activity and in vivo antitumor activity. Bimiralisib hydrochloride induces G1 cell cycle arrest, apoptosis and cell death in cancer cells, while inhibiting cancer cell proliferation, migration, invasion, colony formation and spheroid generation. Bimiralisib hydrochloride upregulates the expression of E2F4. The combination of Bimiralisib hydrochloride with venetoclax enhances therapeutic efficacy in acute myeloid leukemia models. Bimiralisib hydrochloride can be used in cancer-related research .
loading...
    loading...